New York, Feb 12, 2026, 12:05 EST — Regular session
- ICON shares dropped roughly 39% after the company revealed an internal accounting probe and pulled its 2025 guidance.
- The clinical trial outsourcer delayed its full-year 2025 results release until April 30 or earlier.
- Wall Street is holding its breath for updated figures and the U.S. inflation report due Friday.
ICON plc shares dropped roughly 39% to $81.01 by midday Thursday after the contract research company revealed an internal accounting probe and postponed its annual results. The stock slid to a session low of $67.19 but climbed as high as $131.90, with around 14.6 million shares traded.
ICON announced it aims to publish its fourth-quarter and full-year 2025 results by April 30 at the latest. The company is conducting an audit committee-led review of its accounting practices and controls, zeroing in on revenue recognition—the timing of when sales are recorded. ICON anticipates uncovering one or more “material weaknesses,” which are control flaws that could increase the risk of financial misstatements. “The ICON Board of Directors is committed to transparency, accountability and strong governance,” said Chair Ciaran Murray. CEO Barry Balfe added that the company is implementing “corrective actions to enhance our internal controls.” ICON plc
The drop came while the broader market was already feeling the heat, with the S&P 500 tracker SPY slipping roughly 1.1% and the Nasdaq 100 tracker QQQ dropping around 1.6%.
After stronger-than-expected U.S. job growth in January, investors are adjusting their rate forecasts. This data could prompt the Federal Reserve to remain cautious about cutting rates.
ICON reported that preliminary data suggests 2023 and 2024 revenues may have been overstated by under 2% each year. The company also withdrew its full-year 2025 financial guidance. It emphasized that no customer impact has been found related to the practices under investigation.
Analysts jumped on the news fast. Elizabeth Anderson from Evercore ISI put her rating on hold, while Michael Cherny at Leerink Partners downgraded the stock, slashing his price target from $220 to $105. He pointed to ongoing uncertainty and pressure on cancellations and margins, Investors Business Daily reports.
Evercore said it pulled coverage due to a lack of “sufficient fundamental basis” for issuing a rating or target price until revised financials come out, according to StreetInsider. The firm also highlighted a broad range of potential earnings effects depending on any revenue adjustments, emphasizing the uncertainty. Streetinsider
ICON, based in Dublin, offers outsourced clinical trial services to pharmaceutical and biotech companies. These lengthy projects hinge on precise timing and accounting, just as much as on pipeline demand. Minor changes in recognized revenue can significantly impact margins, cash flow, and debt metrics that investors track every quarter.
Yet, several uncertainties remain. The probe might expand, the restatement could get bigger, or deadlines might be pushed back once more — and drawn-out ambiguity threatens to divert management’s focus and shake customer confidence, despite the company’s assurances that service delivery remains unaffected.
Markets are eyeing two key dates: ICON’s postponed 2025 earnings release set for April 30, and the U.S. consumer price index for January, scheduled for Friday, Feb. 13 at 8:30 a.m.
